Beam Therapeutics Inc. (BEAM) Description, Stock price, News & Info.

#ThinkSabio Latest News

Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (#AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation.